InvestorsObserver
×
News Home

Is Catalyst Pharmaceuticals Inc (CPRX) a Bad Choice in Biotechnology Friday?

Friday, November 10, 2023 11:40 AM | InvestorsObserver Analysts

Mentioned in this article

Is Catalyst Pharmaceuticals Inc (CPRX) a Bad Choice in Biotechnology Friday?

A rating of 71 puts Catalyst Pharmaceuticals Inc (CPRX) near the top of the Biotechnology industry according to InvestorsObserver. Catalyst Pharmaceuticals Inc's score of 71 means it scores higher than 71% of stocks in the industry. Catalyst Pharmaceuticals Inc also received an overall rating of 57, putting it above 57% of all stocks. Biotechnology is ranked 52 out of the 148 industries.

Overall Score - 57
CPRX has an Overall Score of 57. Find out what this means to you and get the rest of the rankings on CPRX!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Catalyst Pharmaceuticals Inc Stock Today?

Catalyst Pharmaceuticals Inc (CPRX) stock is trading at $12.96 as of 11:34 AM on Friday, Nov 10, a gain of $0.64, or 5.15% from the previous closing price of $12.32. The stock has traded between $12.41 and $12.99 so far today. Volume today is below average. So far 389,060 shares have traded compared to average volume of 1,271,111 shares. Click Here to get the full Stock Report for Catalyst Pharmaceuticals Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App